<DOC>
	<DOCNO>NCT02168595</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics single ascend IV dos GMI-1271 healthy adult subject .</brief_summary>
	<brief_title>Placebo-controlled Single Dose Study Evaluate Safety Pharmacokinetics GMI-1271 Healthy Volunteers</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , single ascend IV dose study conduct one study center United States ( US ) . One ( 1 ) cohort 12 subject ( 6 active 6 placebo ) two ( 2 ) cohort 8 subject ( 6 active 2 placebo ) plan evaluation . Subjects participate one cohort . Safety assess throughout study serial blood sample urine sample collect safety PK assessment GMI-1271 .</detailed_description>
	<criteria>1 . Healthy adult male and/or female , 19 60 year age , inclusive . 2 . Medically healthy clinically significant screen result ( e.g. , laboratory profile , medical history , vital sign , ECGs , physical examination ) deem PI . 3 . Females childbearing potential must either sexually inactive ( abstinent ) 3 month prior dose use acceptable birth control method 4 . Females must negative pregnancy test time screen prior dose inclusion study . 5 . Understands study procedure inform consent form ( ICF ) , willing able comply protocol . 1 . Subject mentally legally incapacitated significant emotional problem time screen visit expect conduct study . 2 . History presence clinically significant medical psychiatric condition disease opinion PI . 3 . History illness , opinion PI , might confound result study pose additional risk subject participation study . 4 . Hemoglobin level lower limit normal screen checkin . 5 . Any liver function test ( e.g. , AST , ALT , bilirubin ) 1.5x upper limit normal screen checkin . 6 . Positive result screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) . 7 . Seated blood pressure le 90/40 mmHg great 140/90 mmHg screening . 8 . Heart rate lower 40 bpm high 99 bpm screening . 9 . QTc interval &gt; 430 msec male &gt; 450 msec female , history prolong QT syndrome . 10 . Estimated creatinine clearance &lt; 90 ml/min screen checkin . 11 . Blood donation significant blood loss within 56 day prior dose . 12 . Plasma donation within 7 day prior dose . 13 . Participation another clinical trial within 28 day prior dose . The 28day window derive date last study procedure ( last blood collection dose ) previous study Day 1 Period 1 current study . Note : If increase ( &gt; 1.5 x N ) bilirubin present screen additional liver function test may perform ( ALT , AST , ALP , albumin , direct indirect bilirubin ) determine increase bilirubin due GilbertMeulengracht syndrome . If consistent Gilbert 's syndrome , Investigator Sponsor may decide consider exclusion . Any decision document study record .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>healthy volunteer , GMI-1271</keyword>
</DOC>